Tranexamic acid is an antifibrinolytic agent that prevents the breakdown of blood clots by inhibiting plasmin activation. Its primary relevance to healthspan is not systemic, but rather its topical application to treat melasma, a form of skin hyperpigmentation often associated with aging and sun exposure. There is no current evidence to support its systemic use for extending lifespan or improving general healthspan metrics.
Verdict
Topically useful for melasma; avoid systemic use for healthspan due to risks.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
High
EVIDENCE GRADE
A
MONTHLY COST
$20 - $100
Protocol
- No established healthspan protocol exists; it is clinically used for bleeding disorders or topically for melasma.
Flags
- Systemic use significantly increases the risk of blood clots (thrombosis, stroke, pulmonary embolism).
- Requires a prescription and medical supervision for any use.
- Contraindicated in individuals with a history of or risk for thromboembolic disease.
- Interacts with hormonal contraceptives, further increasing clot risk.
- No evidence supports systemic use for longevity or anti-aging purposes.